NasdaqGS - Nasdaq Real Time Price USD

Vertex Pharmaceuticals Incorporated (VRTX)

Compare
490.80 +0.48 (+0.10%)
At close: 4:00 PM EDT
490.90 +0.10 (+0.02%)
After hours: 5:21 PM EDT
Loading Chart for VRTX
DELL
  • Previous Close 490.32
  • Open 488.46
  • Bid 490.76 x 100
  • Ask 491.22 x 100
  • Day's Range 486.25 - 491.99
  • 52 Week Range 340.20 - 498.77
  • Volume 965,631
  • Avg. Volume 1,180,139
  • Market Cap (intraday) 126.652B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 31.87
  • EPS (TTM) 15.40
  • Earnings Date Aug 1, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 481.41

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

www.vrtx.com

5,400

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VRTX

View More

Performance Overview: VRTX

Trailing total returns as of 7/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

VRTX
20.62%
S&P 500
13.78%

1-Year Return

VRTX
35.41%
S&P 500
19.64%

3-Year Return

VRTX
144.79%
S&P 500
23.01%

5-Year Return

VRTX
180.07%
S&P 500
80.58%

Compare To: VRTX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VRTX

View More

Valuation Measures

Annual
As of 7/23/2024
  • Market Cap

    126.53B

  • Enterprise Value

    117.08B

  • Trailing P/E

    31.82

  • Forward P/E

    30.40

  • PEG Ratio (5yr expected)

    0.66

  • Price/Sales (ttm)

    12.55

  • Price/Book (mrq)

    6.82

  • Enterprise Value/Revenue

    11.50

  • Enterprise Value/EBITDA

    23.39

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    39.46%

  • Return on Assets (ttm)

    12.82%

  • Return on Equity (ttm)

    24.38%

  • Revenue (ttm)

    10.18B

  • Net Income Avi to Common (ttm)

    4.02B

  • Diluted EPS (ttm)

    15.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.17B

  • Total Debt/Equity (mrq)

    3.89%

  • Levered Free Cash Flow (ttm)

    3.31B

Research Analysis: VRTX

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

325.00 Low
481.41 Average
490.80 Current
589.00 High
 

Company Insights: VRTX

Research Reports: VRTX

View More
  • The Argus Min Vol Model Portfolio

    Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.

     
  • The Argus Min Vol Model Portfolio

    Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.

     
  • The driver of the S&P 500 (SPX), the Nasdaq 100 (QQQ), and the Nasdaq Composite has been semiconductor stocks, led by Nvidia (NVDA).

    The driver of the S&P 500 (SPX), the Nasdaq 100 (QQQ), and the Nasdaq Composite has been semiconductor stocks, led by Nvidia (NVDA). That stock has soared 156% in 2024, with Micron Technology (MU +64%), Broadcom (AVGO +49%), Qualcomm (QCOM +48%) and Applied Materials (AMAT +46%) jumping as well. The slope of the semiconductor chart continues to steepen and there is a potential bearish momentum divergence. The iShares Semiconductor (SOXX) recently was 30% above its 50-week exponential average and quite extended. A pullback would be welcome, but sooner or later, the semis could go parabolic -- which is fun while it lasts, but is always the ending price blowoff for an advance. Most of the other tech industries have not done well in 2024, so it's also possible that funds taking profits in semis will move into other areas that may benefit from AI later on. Interestingly, four of the biggest Technology sector gainers recently were beaten-down stocks such as Accenture (ACN), Epam Systems (EPAM), Salesforce.com (CRM), and Cognizant Technology (CTSH). All four traced out weekly up-patterns (closed above their prior week highs) while ACN traced out a monthly up. Those stocks are clear AI beneficiaries, but likely down the road (though maybe not that far down the road). Their technical turnaround is still early as they all recently hit intermediate-term lows. These stocks could have seen "forced" selling in recent months as many investors needed funds to chase the semis. Of interest, there has been some massive insider selling at Nvidia, including from its CEO, Jensen Huang. That's certainly not surprising. (Mark Arbeter, CMT)

     
  • Raising target price to $550

    Vertex Pharmaceuticals develops therapies to address cystic fibrosis and other diseases. The company was founded in 1989 in Cambridge, Massachusetts and has 5,400 employees. It has research programs and facilities in the U.S., the UK, and Canada. The shares are a component of the S&P 500.

    Rating
    Price Target
     

People Also Watch